These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11516995)

  • 1. Yellow fever vector live-virus vaccines: West Nile virus vaccine development.
    Arroyo J; Miller CA; Catalan J; Monath TP
    Trends Mol Med; 2001 Aug; 7(8):350-4. PubMed ID: 11516995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.
    Guy B; Guirakhoo F; Barban V; Higgs S; Monath TP; Lang J
    Vaccine; 2010 Jan; 28(3):632-49. PubMed ID: 19808029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.
    Arroyo J; Miller C; Catalan J; Myers GA; Ratterree MS; Trent DW; Monath TP
    J Virol; 2004 Nov; 78(22):12497-507. PubMed ID: 15507637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A live, attenuated recombinant West Nile virus vaccine.
    Monath TP; Liu J; Kanesa-Thasan N; Myers GA; Nichols R; Deary A; McCarthy K; Johnson C; Ermak T; Shin S; Arroyo J; Guirakhoo F; Kennedy JS; Ennis FA; Green S; Bedford P
    Proc Natl Acad Sci U S A; 2006 Apr; 103(17):6694-9. PubMed ID: 16617103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.
    Pletnev AG; Claire MS; Elkins R; Speicher J; Murphy BR; Chanock RM
    Virology; 2003 Sep; 314(1):190-5. PubMed ID: 14517072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for development of a vaccine against the West Nile virus.
    Monath TP
    Ann N Y Acad Sci; 2001 Dec; 951():1-12. PubMed ID: 11797767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.
    Monath TP; Seligman SJ; Robertson JS; Guy B; Hayes EB; Condit RC; Excler JL; Mac LM; Carbery B; Chen RT;
    Vaccine; 2015 Jan; 33(1):62-72. PubMed ID: 25446819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. West Nile virus vaccine.
    Monath TP; Arroyo J; Miller C; Guirakhoo F
    Curr Drug Targets Infect Disord; 2001 May; 1(1):37-50. PubMed ID: 12455232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus).
    Langevin SA; Arroyo J; Monath TP; Komar N
    Am J Trop Med Hyg; 2003 Jul; 69(1):78-80. PubMed ID: 12932102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.
    Dayan GH; Pugachev K; Bevilacqua J; Lang J; Monath TP
    Viruses; 2013 Dec; 5(12):3048-70. PubMed ID: 24351795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.
    Maximova OA; Speicher JM; Skinner JR; Murphy BR; St Claire MC; Ragland DR; Herbert RL; Pare DR; Moore RM; Pletnev AG
    Vaccine; 2014 May; 32(26):3187-97. PubMed ID: 24736001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
    Minke JM; Siger L; Karaca K; Austgen L; Gordy P; Bowen R; Renshaw RW; Loosmore S; Audonnet JC; Nordgren B
    Arch Virol Suppl; 2004; (18):221-30. PubMed ID: 15119777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. West Nile virus vaccines.
    Hall RA; Khromykh AA
    Expert Opin Biol Ther; 2004 Aug; 4(8):1295-305. PubMed ID: 15268663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of chimaeric West Nile virus attenuated vaccine candidate based on the Japanese encephalitis vaccine strain SA14-14-2.
    Li XF; Zhao W; Lin F; Ye Q; Wang HJ; Yang D; Li SH; Zhao H; Xu YP; Ma J; Deng YQ; Zhang Y; Qin ED; Qin CF
    J Gen Virol; 2013 Dec; 94(Pt 12):2700-2709. PubMed ID: 24092759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
    Hanley KA; Goddard LB; Gilmore LE; Scott TW; Speicher J; Murphy BR; Pletnev AG
    Vector Borne Zoonotic Dis; 2005; 5(1):1-10. PubMed ID: 15815144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.